Ascelia Pharma (One-pager): The market is still only partly discounting likelihood of approval and successful launch of Orviglance
Ascelia Pharma participated in an event with HCA Capital last week following the release of the 1. quarter report. At the event Deputy CEO and Chief Commercial Officer Julie Waras Brogren explained the company’s plans for Orviglance for the coming quarters following the recent completion of its pivotal SPARKLE phase 3 study, and the recent release of very strong headline data from the study. During the event the Ascelia Pharma share rose almost 10 percent but since then the share is down again like the rest of the BioTech and Life Science in general. This comes even as Julie Waras Brogren confirmed ambitions at the event that an Orphan Drug Designation and serving an unmet need will help Orviglance achieve a large share of the addressable market of approximately USD 400 million annually in US. It is not unlikely that Orviglance will begin to be sold through partnerships already late 2025 or in the beginning of 2026.
While down approximately 30 percent the last five weeks, the share is still up approximately 180 percent this year, but interestingly our updated company guided model in the Ascelia Pharma One-Pager indicates that the market still implicitly assess a relatively low likelihood of FDA-approval and subsequent successful launch of Oviglance through a partnership.
Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup 12:30 PM 29-05-2024.
Ascelia Pharma
Ascelia Pharma är ett läkemedelsbolag. Bolaget är specialiserat på utveckling av särläkemedel inom onkologi (cancer). Bolaget utvecklar diverse läkemedelskandidater, där störst användning återfinns inom behandling av cancer som drabbat lever och magsäck. Bolaget grundades år 2000 och har huvudkontor i Malmö, Sverige, men är verksamt på en global marknad.
Read more on company page